International Stroke Conference (ISC)

In a recent study presented at ISC 2024, results revealed that patients who used assisted reproductive technologies therapy during hospitalization for delivery had a higher risk of stroke than those who did not use such therapies.

A recent study showed anticoagulation reduced ischemic stroke risk in patients with cervical artery dissection; however, cautioned is warned about the importance of transitioning to antiplatelet therapy at a certain point.

Topline results from the RESCUE trial indicate that RNS60, an anti-inflammatory agent, demonstrates safety and potential efficacy in acute ischemic stroke.

The assistant professor of neurosurgery and biomedical informatics at the State University of New York at Buffalo provided commentary on the significant findings from the EMBOLISE trial presented at the 2024 International Stroke Conference. [WATCH TIME: 4 minutes]

Using a cohort of more than 20,000 patients with ischemic stroke, those on AI-CDSS experienced less vascular events of hemorrhagic stroke, myocardial infarction, or vascular death.

Tirofiban treatment in acute ischemic stroke reduced early neurological deterioration compared to oral antiplatelet therapy alone, warranting further investigation.

Elezanumab's biomarker analysis in stroke patients underscores its potential as a neuroprotective therapy for acute ischemic stroke management.

Over a 90-day period, investigators observed significantly lower functional outcomes on modified Rankin Scale and similar rates of bleeding and death when compared with control.

The associate professor of neurology at Weill Cornell Medicine talked about a recent study that revealed that minimally invasive surgery significantly reduced the risk of mortality in patients with nontraumatic intracerebral hemorrhage. [WATCH TIME: 4 minutes]

The chief of the division of stroke and hospital neurology at Weill Cornell Medicine shared some of his thoughts on the promising clinical trials being presented at the 2024 International Stroke Conference. [WATCH TIME: 3 minutes]

In comparison with placebo, slightly better outcomes on modified Rankin Scale were observed with adrenomedullin.

The director of Cleveland Clinic’s Cerebrovascular Center provided clinical perspective on the treatment decisions mobile stroke units face, and whether directly transferring patients to angiography suite is necessary.

As a recap from ISC 2023, get caught up on some of the latest news in stroke as the NeurologyLive® team shares some of our data updates and expert insights.

The vascular and interventional neurologist at Cleveland Clinic provided insight on a study presented at the 2023 International Stroke Conference that observed the clinical effectiveness of mechanical thrombectomy beyond 24 hours. [WATCH TIME: 6 minutes]

The medical director of the Cooper Neurological Institute spoke at the 2023 International Stroke Conference about notable research themes from the meeting. [WATCH TIME: 10 minutes]

The director of Cleveland Clinic’s Cerebrovascular Center discussed the decisions mobile stroke units face and why opting for direct transfer to angiography is meant for certain scenarios. [WATCH TIME: 3 minutes]

The director of Cleveland Clinic’s Cerebrovascular Center provided perspective on a new study presented at the International Stroke Conference on experiences of poststroke patients taken directly to angiography suite. [WATCH TIME: 3 minutes]

Investigators Macarena Hernandez, PhD, and Marc Ribo, MD, provided commentary on positive phase 2a findings assessing ApTOLL in combination with EVT in patients with ischemic stroke.

Blood pressure medications may not be safe or effective to use for lowering systolic blood pressure following endovascular treatment for acute ischemic stroke.

The professor of neurology at Harvard Medical School spoke at the 2023 ISC Conference about highlights from the STROKE-AF study after a 3-year follow-up. [WATCH TIME: 5 minutes]

In comparison with those who underwent additional imaging, patients with large vessel occlusion who directly went to angiography suite had higher mortality, but with no difference in functional outcome.

At the conclusion of the trial, treatment with 0.2 mg/kg of ApTOLL with EVT resulted in reduced brain edema and hemorrhagic transformation, as well as fewer deaths than placebo and 0.05 mg groups.

Patients with noncardioembolic ischemic stroke do not typically monitor post-stroke longterm to detect atrial fibrillation although findings from a trial follow-up suggest otherwise.

The medical director of stroke at Fairview Hospital, an affiliate of Cleveland Clinic, provided perspective on a new intervention that improves communication and reduces hospital readmission for stroke.

After Rapid LVO installation, CTA to groin puncture time decreased and 90-day clinical outcomes, expressed using modified Rankin Scale, were improved.

The study found the approach could be utilized in the intensive care unit without adverse effects on neurological or functional outcomes.

There was no significant association between Black race and clinical outcome following mechanical thrombectomy.

The data safety monitoring board reviewed 90-day outcomes for the first 200 patients, recommending that investigators continue the study as it currently stands.

More than 30% of the lower dose tenecteplase group achieved major reperfusion without symptomatic intracranial hemorrhage at 24 to 48 hours after thrombolysis.

A greater proportion of those treated with EVT had modified Rankin Scale scores of 0-3 at 90 days and NIHSS improvements of at least 8 points or more at 48 hours, relative to standard medical therapy.